Kwong K. Wong, Ph.D.
Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery
About Dr. Wong
Kwong K. Wong, Ph.D. has a broad background in biology and biochemistry, with specific training in molecular genetics and genomics, and in DNA sequencing analyses, gene expression profiling and data mining. He is an inventor or co-inventor in 6 US issued patents. His laboratory is interested in deciphering the molecular pathogenesis of ovarian cancer with a translational goal to identify potential prognostic biomarkers and therapeutic targets for individualized therapy. His current research focus is on rare ovarian cancer such as low-grade serous carcinoma and ovarian clear cell carcinoma. One of his projects is to decipher the resistance mechanisms of low-grade ovarian serous carcinoma to MEK inhibitors. He has been collaborating with faculty at University of Texas MD Anderson Cancer Center and other institutions. Dr. Wong is a regular member of the graduate faculty for the University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences. He has trained numerous graduate students and clinical fellows and has been named the Faculty Educator of the Month.
Current Projects:
1) To understand the molecular pathogenesis in low-grade serous ovarian cancer and develop novel therapeutics. 2) To decipher the molecular mechanisms of chemoresistance in ovarian cancer. 3) To identify synthetic lethal genes in ovarian cancer cells. 4) To develop therapeutics for ovarian clear cell carcinomas.
Present Title & Affiliation
Primary Appointment
Professor, Department of Gynecologic Oncology and Reproductive Medicine - Research, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Dr. Wong's major research interest is to decipher the molecular pathogenesis of ovarian cancer with a translational goal to identify potential prognostic biomarkers and therapeutic targets for individualized therapy. Both genomics and mouse model approaches are being pursued in his laboratory. Ovarian cancer is a heterogeneous disease with complex molecular and genetic changes. There are five major histological subtypes of epithelial ovarian cancer: high-grade serous carcinoma (HGSC), low-grade serous carcinoma (LGSC), ovarian clear cell carcinoma (OCCC), mucinous epithelial ovarian carcinoma, and ovarian endometrioid carcinoma. Mutations in several genes have been identified as contributing to various ovarian cancer subtypes. TP53 mutations are present in almost all HGSCs, and BRCA1/2 mutations are present in approximately 10% of HGSCs. However, other actionable mutations are infrequent in HGSCs. On the other hand KRAS activating mutations are present in more than 30% of LGSCs and more than 40% of mucinous ovarian carcinomas. PIK3CA activating mutations are present in more than 35% of OCCCs and more than 20% of ovarian endometrioid carcinomas. BRAF activating mutations are detected in both LGSCs (2-33%) and mucinous ovarian carcinomas (~10%). ARID1A, the AT-rich interactive domain A1 gene, is mutated in more than 45% of OCCCs and more than 25% of ovarian endometrioid carcinomas. Thus, there are many opportunities to develop targeted therapies for these specific histological subtypes with actionable mutations.
Education & Training
Degree-Granting Education
| 1990 | The Chinese University of Hong Kong, Hong Kong, CHN, PHD, Biology (Molecular Biology) |
| 1987 | The Chinese University of Hong Kong, Hong Kong, CHN, MPhil, Biology (Bacterial Genetics) |
| 1984 | The Chinese University of Hong Kong, Hong Kong, CHN, BS, Biology/Biochemistry (Hons) |
Postgraduate Training
| 1995-1996 | Research Fellowship, Battelle Memorial Institute, Pacific Northwest National Laboratory, Richland, WA |
| 1990-1995 | Research Fellowship, Genomics, California Institute of Biological Research, La Jolla, CA |
Honors & Awards
| 2016 | Faculty Educator of the Month (August), UT MD Anderson Cancer Center |
| 2010 | Finalist, Julie and Ben Rogers Award for Excellence in the area of Education, UT MD Anderson Cancer Center |
| 2010 | Who's Who in America, Marquis Who's Who |
| 2003 | Children's Oncology Group Young Investigator Award, Children's Oncology Group |
| 2000 | Director's Award, Pacific Northwest National Laboratory |
| 2000 | EHSD Outstanding Performance Award, Pacific Northwest National Laboratory |
| 1998 | Certificate of Appreciation, Office of Research, Department of Energy |
| 1988 | Sir Edward Yude Memorial Scholarship |
| 1984 | LNP Award for Balanced Education, The Chinese University of Hong Kong |
Selected Publications
Peer-Reviewed Articles
- Ferri-Borgogno S, Zhu Y, Sheng J, Burks JK, Gomez JA, Wong KK, Wong STC, Mok SC. Spatial Transcriptomics Depict Ligand-Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors. Cancer Res 83(9):1503-1516, 2023. PMID: 36787106.
- Wong KK, Bateman NW, Ng CW, Tsang YTM, Sun CS, Celestino J, Nguyen TV, Malpica A, Hillman RT, Zhang J, Futreal PA, Rojas C, Conrads KA, Hood BL, Dalgard CL, Wilkerson MD, Phippen NT, Conrads TP, Maxwell GL, Sood AK, Gershenson DM. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors. J Transl Med 20(1):606, 2022. e-Pub 2022. PMID: 36528667.
- Corvigno S, Johnson AM, Wong KK, Cho MS, Afshar-Kharghan V, Menter DG, Sood AK. Novel markers for liquid biopsies in cancer management: Circulating platelets and extracellular vesicles. Mol Cancer Ther 21(7):2022 Jul 5;21(7):1067-1075, 2022. e-Pub 2022. PMID: 35545008.
- Gershenson DM, Sun CC, Westin SN, Eyada M, Cobb LP, Nathan LC, Sood AK, Malpica A, Hillman RT, Wong KK. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. Gynecol Oncol 165(3):560-567, 2022. e-Pub 2022. PMID: 35606067.
- Ng CW, Wong KK. Impact of estrogen receptor expression on prognosis of ovarian cancer according to antibody clone used for immunohistochemistry: a meta-analysis. J Ovarian Res 15(1):63, 2022. e-Pub 2022. PMID: 35610648.
- Kun E, Tsang YTM, Ng CW, Gershenson DM, Wong KK. MEK inhibitor resistance mechanisms and recent developments in combination trials. Cancer Treat Rev 92:102137, 2021. e-Pub 2020. PMID: 33340965.
- Choi PW, Bahrampour A, Ng SK, Liu SK, Qiu W, Xie F, Kuo WP, Kwong J, Hales KH, Hales DB, Wong KK, Norwitz ER, Chow CK, Berkowitz RS, Ng SW. Characterization of miR-200 family members as blood biomarkers for human and laying hen ovarian cancer. Sci Rep 10(1):20071, 2020. e-Pub 2020. PMID: 33208870.
- Kun EHS, Tsang YTM, Lin S, Pan S, Medapalli T, Malpica A, Richards JS, Gershenson DM, Wong KK. Differences in gynecologic tumor development in Amhr2-Cre mice with KRASG12D or KRASG12V mutations. Sci Rep 10(1):20678, 2020. e-Pub 2020. PMID: 33244099.
- Izaguirre DI, Ng CW, Kwan SY, Kun EH, Tsang YTM, Gershenson DM, Wong KK. The Role of GDF15 in Regulating the Canonical Pathways of the Tumor Microenvironment in Wild-Type p53 Ovarian Tumor and Its Response to Chemotherapy. Cancers (Basel) 12(10), 2020. e-Pub 2020. PMID: 33086658.
- Cobb LP, Sun CC, Iyer R, Nick AM, Fleming ND, Westin SN, Sood AK, Wong KK, Silva EG, Gershenson DM. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Gynecol Oncol 158(3):653-658, 2020. e-Pub 2020. PMID: 32709538.
- Zhang L, Kwan SY, Wong KK, Solaman PT, Lu KH, Mok SC. Pathogenesis and Clinical Management of Uterine Serous Carcinoma. Cancers (Basel) 12(3), 2020. e-Pub 2020. PMID: 32183290.
- Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, Wong KK, Covens A, O'Malley DM, Lecuru F, Cobb LP, Caputo TA, May T, Huang M, Siemon J, Fernández ML, Ray-Coquard I, Gershenson DM. Low-grade serous ovarian cancer: State of the science. Gynecol Oncol 156(3):715-725, 2020. e-Pub 2020. PMID: 31969252.
- Kwan SY, Au-Yeung CL, Yeung TL, Rynne-Vidal A, Wong KK, Risinger JI, Lin HK, Schmandt RE, Yates MS, Mok SC, Lu KH. Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) promotes uterine serous cancer cell proliferation and cell cycle progression. Cancers (Basel) 12(1):118, 2020. e-Pub 2020. PMID: 31906456.
- Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Eun YG, Rose J, Bartholomeusz G, Ivan C, Lee JS, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein G, Sood AK. PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Mol Cancer Ther 18(1):162-172, 2019. e-Pub 2018. PMID: 30305341.
- Yeung TL, Tsai CC, Leung CS, Au Yeung CL, Thompson MS, Lu KH, Freedman RS, Birrer MJ, Wong KK, Mok SC. ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression. Cancers (Basel) 10(12), 2018. e-Pub 2018. PMID: 30469497.
- Padmanabhan A, Candelaria N, Wong KK, Nikolai BC, Lonard DM, O'Malley BW, Richards JS. USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells. Nat Commun 9(1):1270, 2018. e-Pub 2018. PMID: 29593334.
- Matsuo K, Wong KK, Fotopoulou C, Blake EA, Robertson SE, Pejovic T, Frimer M, Pardeshi V, Hu W, Choi JS, Sun CC, Richmond AM, Marcus JZ, Hilliard MAM, Mostofizadeh S, Mhawech-Fauceglia P, Abdulfatah E, Post MD, Saglam O, Shahzad MMK, Karabakhtsian RG, Ali-Fehmi R, Gabra H, Roman LD, Sood AK, Gershenson DM. Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma. J Surg Oncol 117(2):236-244, 2018. e-Pub 2017. PMID: 28787528.
- Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, Birrer MJ, Mok SC. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest 128(2):589-606, 2018. e-Pub 2017. PMID: 29251630.
- Raza A, Tsang YTM, Yu Z, Adesina A, Aldape K, Lau CC, Wong KK. Overexpression of Sema3E and Sema5A in pilocytic astrocytoma. Advances in Modern Oncology Research 3(5):232-240, 2017.
- Yeung TL, Leung CS, Wong KK, Gutierrez-Hartmann A, Kwong J, Gershenson DM, Mok SC. ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells. Oncotarget 8(10):16951–16963, 2017. e-Pub 2017. PMID: 28199976.
- Jia N, Wang J, Li Q, Tao X, Chang K, Hua K, Yu Y, Wong KK, Feng W. DNA methylation promotes paired box 2 expression via myeloid zinc finger 1 in endometrial cancer. Oncotarget 7(51):84785-84797, 2016. PMID: 27764784.
- Kwan SY, Cheng X, Tsang YT, Choi JS, Kwan SY, Izaguirre DI, Kwan HS, Gershenson DM, Wong KK. Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells. Oncotarget 7(35):56933-56943, 2016. e-Pub 2016. PMID: 27486766.
- Takekuma M, Wong KK, Coleman R. A long-surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor selumetinib. Gynecologic Oncology Research and Practice 3:1-5, 2016.
- Ren YA, Mullany LK, Liu Z, Herron AJ, Wong KK, Richards JS. Mutant p53 promotes epithelial ovarian cancer by regulating tumor differentiation, metastasis, and responsiveness to steroid hormones. Cancer Res 76(8):2206-2218. e-Pub 2016. PMID: 26964623.
- Lin CC, Tsai CC, Lee JM, Fang CH, Chang KS, Wong KK, Lin CT, Qiu JT. The efficacy of a novel vaccine approach using tumor cells that ectopically express a codon-optimized murine GM-CSF in a murine tumor model. Vaccine 34(1):134-41, 2016. e-Pub 2015. PMID: 26546261.
- Au Yeung CL, Co NN, Tsuruga T, Yeung TL, Kwan SY, Leung CS, Li Y, Lu ES, Kwan K, Wong KK, Schmandt R, Lu KH, Mok SC. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun 7:11150, 2016. e-Pub 2016. PMID: 27021436.
- Gershenson DM, Sun CC, Wong KK. Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum. Br J Cancer 113(9):1254-8, 2015. e-Pub 2015. PMID: 26484411.
- Mullany LK, Wong KK, Marciano DC, Katsonis P, King-Crane ER, Ren YA, Lichtarge O, Richards JS. Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival. Neoplasia 17(10):789-803, 2015. PMID: 26585234.
- Qiu MT, Fan Q, Zhu Z, Kwan SY, Chen L, Chen JH, Ying ZL, Zhou Y, Gu W, Wang LH, Cheng WW, Zeng J, Wan XP, Mok SC, Wong KK, Bao W. KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1. Oncotarget 6(31):31702-20, 2015. PMID: 26397136.
- Gershenson DM, Bodurka DC, Lu KH, Nathan LC, Milojevic L, Wong KK, Malpica A, Sun CC. Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. J Clin Oncol 33(24):2675-82, 2015. e-Pub 2015. PMID: 26195696.
- Crane EK, Kwan SY, Izaguirre DI, Tsang YT, Mullany LK, Zu Z, Richards JS, Gershenson DM, Wong KK. Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas. PLoS One 10(8):e0135101, 2015. e-Pub 2015. PMID: 26248031.
- Mullany LK, Liu Z, Wong KK, Deneke V, Ren YA, Herron A, Richards JS. Tumor Repressor Protein 53 and Steroid Hormones Provide a New Paradigm for Ovarian Cancer Metastases. Mol Endocrinol 28(1):127-137, 2014. e-Pub 2013. PMID: 24264574.
- Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC. Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun 5:5092, 2014. e-Pub 2014. PMID: 25277212.
- Tone AA, McConechy MK, Yang W, Ding J, Yip S, Kong E, Wong KK, Gershenson DM, Mackay H, Shah S, Gilks B, Tinker AV, Clarke B, McAlpine JN, Huntsman D. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. BMC Cancer 14(1):982, 2014. e-Pub 2014. PMID: 25523272.
- Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK, Mok SC, Gershenson DM. Poor survival with wild-type TP53 ovarian cancer?. Gynecol Oncol 130(3):565-569, 2013. e-Pub 2013. PMID: 23800698.
- Tsang YT, Deavers MT, Sun CC, Kwan SY, Kuo E, Malpica A, Mok SS, Gershenson DM, Wong KK. KRAS (but not BRAF) mutations in ovarian serous borderline tumor are associated with recurrent low-grade serous carcinoma. J Pathol 231(4):449-456. e-Pub 2013. PMID: 24105490.
- Yang G, Mercado-Uribe I, Multani AS, Sen S, Shih IeM, Wong KK, Gershenson DM, Liu J. RAS Promotes Tumorigenesis through Defective Cytokinesis Mediated by Aurora-A and BRCA2. Int J Cancer 133(2):275-85, 2013. e-Pub 2013. PMID: 23319376.
- Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ, Mok SC. TGF-b modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Research 73(16):5016-5028. e-Pub 2013.
- Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC. Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage High-Grade Serous Ovarian Cancer. Clin Cancer Res 19(4):808-820, 2013. e-Pub 2013. PMID: 23344261.
- Song H, Kwan SY, Izaguirre DI, Zu Z, Tsang YT, Tung CS, King ER, Mok SC, Gershenson DM, Wong KK. PAX2 expression in ovarian cancer. Int J Mol Sci 14(3):6090-6105, 2013. e-Pub 2013. PMID: 23502471.
- Mullany LK, Liu Z, King ER, Wong KK, Richards JS. Wild Type Tumor Repressor Protein 53 (TRP53) Promotes Ovarian Cancer Cell survival. Endocrinology 153(4):1638-48, 2012. e-Pub 2012. PMID: 22396451.
- King ER, Zu Z, Tsang YT, Deavers MT, Malpica A, Mok SC, Gershenson DM, Wong KK. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecol Oncol 123(1):13-18, 2011. e-Pub 2011. PMID: 21726895.
- Mullany LK, Fan HY, Liu Z, White LD, Marshall A, Gunaratne P, Anderson ML, Creighton CJ, Xin L, Deavers M, Wong KK, Richards JS. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene 30(32):3522-3536, 2011. e-Pub 2011. PMID: 21423204.
- Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MM, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK. Targeting Src in mucinous ovarian carcinoma. Clin Cancer Res 17(16):5367-5378, 2011. e-Pub 2011. PMID: 21737505.
- King ER, Tung CS, Tsang YT, Zu Z, Lok GT, Deavers MT, Malpica A, Wolf JK, Lu KH, Birrer MJ, Mok SC, Gershenson DM, Wong KK. The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer. Am J Surg Pathol 35(6):904-912, 2011. e-Pub 2011. PMID: 21451362.
- Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, Lu KH, Gershenson DM. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol 177(4):1611-1617, 2010. e-Pub 2010. PMID: 20802181.
- Mine T, Matsueda S, Gao H, Li Y, Wong KK, Peoples GE, Ferrone S, Ioannides CG. Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44Hi progenitors of taxol-resistant ovarian cancer cells. Oncol Rep 23(6):1537-43, 2010. PMID: 20428807.
- Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, Barrett JC, Wong WH, Welch WR, Berkowitz RS, Birrer MJ. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell 16(6):521-32, 2009. PMID: 19962670.
- Mine T, Matsueda S, Li Y, Tokumitsu H, Gao H, Danes C, Wong KK, Wang X, Ferrone S, Ioannides CG. Breast cancer cells expressing stem cell markers CD44(+) CD24 (lo) are eliminated by Numb-1 peptide-activated T cells. Cancer Immunol Immunother 58(8):1185-1194, 2009. e-Pub 2008. PMID: 19048252.
- Adesina AM, Lopez-Terrada D, Wong KK, Gunaratne P, Nguyen Y, Pulliam J, Margolin J, Finegold MJ. Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum Pathol 40(6):843-53, 2009. e-Pub 2009. PMID: 19200578.
- Wang J, Man TK, Wong KK, Rao PH, Leung HCE, Guerra R, Lau CC. Genome-wide analysis of copy number variations in normal population identified by SNP arrays. The Open Biology J 2(12):54-65, 2009.
- Kwong J, Chan FL, Wong KK, Birrer MJ, Archibald KM, Balkwill FR, Berkowitz RS, Mok SC. The inflammatory cytokine tumor necrosis factor-alpha confers precancerous phenotype in a organoid model of normal human ovarian surface eipithelial cells. Neoplasia 11(6):529-541, 2009. PMID: 19484142.
- Tung CS, Mok SC, Tsang YT, Zu Z, Song H, Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, Gershenson DM, Wong KK. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol 22(9):1243-1250, 2009. e-Pub 2009. PMID: 19525924.
- Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res 14(17):5437-46, 2008. PMID: 18765535.
- Park DC, Yeo SG, Wilson MR, Yerbury JJ, Kwong J, Welch WR, Choi YK, Birrer MJ, Mok SC, Wong KK. Clusterin interacts with paclitaxel and confer paclitaxel resistance in ovarian cancer. Neoplasia 10(9):964-72, 2008. PMID: 18714397.
- Shu Q, Wong KK, Su JM, Adesina AM, Yu LT, Tsang YT, Antalffy BC, Baxter P, Perlaky L, Yang J, Dauser RC, Chintagumpala M, Blaney SM, Lau CC, Li XN. Primary tumor-based orthotopic xenograft mouse models of pediatric brain tumors replicate their biological heterogeneity and preserve cancer stem cell pool during serial in vivo subtransplantations. Stem Cells 26(6):1414-1424, 2008. e-Pub 2008. PMID: 18403755.
- Takei H, Yogeswaren ST, Wong KK, Mehta V, Chintagumpala M, Dauser RC, Lau CC, Adesina AM. Expression of oligodendroglial differentiation markers in pilocytic astrocytomas identifies two clinical subsets and shows a significant correlation with proliferation index and progression free survival. J Neurooncol 86(2):183-190, 2008. e-Pub 2007. PMID: 17690840.
- Wong KK, Lu KH, Malpica A, Bodurka DC, Shvartsman HS, Schmandt RE, Thornton AD, Deavers MT, Silva EG, Gershenson DM. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol 26(4):404-409, 2007. PMID: 17885490.
- Li XN, Shu Q, Su JM, Adesina AM, Wong KK, Perlaky L, Antalffy BA, Blaney SM, Lau CC. Differential expression of surviving splice isoforms in medulloblastomas. Neuropathol Appl Neurobiol 33(1):67-76, 2007. PMID: 17239009.
- Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, Welch WR, Berkowitz RS, Mok SC. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 25(16):2281-7, 2007. PMID: 17538174.
- Wong KK, Tsang YT, Chang YM, Su J, Di Francesco AM, Meco D, Riccardi R, Perlaky L, Dauser RC, Adesina A, Bhattacharjee M, Chintagumpala M, Lau CC. Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. Cancer Res 66(23):11172-11178, 2006. PMID: 17145861.
- Li Y, Wong KK, Matsueda S, Efferson CL, Chang DZ, Ioannides CG, Tsuda N. Mitogen stimulation activates different signaling pathways in early- and late-divided T cells as revealed by cDNA microarray analysis. Int J Mol Med 18(6):1127-39, 2006. PMID: 17089018.
- Kwong J, Lee JY, Wong KK, Zhou X, Wong DT, Lo KW, Welch WR, Berkowitz RS, Mok SC. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia 8(4):268-78, 2006. PMID: 16756719.
- Feltmate CM, Lee KR, Johnson M, Schorge JO, Wong KK, Hao K, Welch WR, Bell DA, Berkowitz RS, Mok SC. Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas. Clin Cancer Res 11(21):7651-7657, 2005. PMID: 16278384.
- Tsuda H, Ito YM, Ohashi Y, Wong KK, Hashiguchi Y, Welch WR, Berkowitz RS, Birrer MJ, Mok SC. Identification of over-expression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res 11(19):6880-6888, 2005. PMID: 16203778.
- Man TK, Chintagumpala M, Visvanathan J, Shen J, Perlaky L, Hicks J, Johnson M, Davino N, Murray J, Helman L, Meyer W, Triche T, Wong KK, Lau CC. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res 65(18):8142-8150, 2005. PMID: 16166288.
- Wong KK, Chang YM, Tsang YTM, Perlaky L, Su J, Adesina A, Armstrong DL, Bhattacharjee M, Dauser R, Blaney SM, Chintagumpala M, Lau CC. Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide microarray reveals two potential subgroups. Cancer Res 65(1):76-84, 2005. PMID: 15665281.
- Huddleston HG, Wong KK, Welch WR, Berkowitz RS, Mok SC. Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol 96(1):77-83, 2005. PMID: 15589584.
- Wong KK, Tsang YTM, Shen J, Cheng RS, Chang YM, Man TK, Lau CC. Allelic imbalance analysis by high-density single nucleotide polymorphic allele (SNP) array with whole genome amplified DNA. Nucleic Acids Res 32(9):e69, 2004. PMID: 15148342.
- Tsuda H, Birrer MJ, Ito YM, Ohashi Y, Lin M, Lee C, Wong WH, Rao P, Lau CC, Berkowitz RS, Wong KK, Mok SC. Identification of DNA copy-number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform. Cancer Genet Cytogenet 155(2):97-107, 2004. PMID: 15571795.
- Tsang YT, Chang YM, Lu X, Rao PH, Lau CC, Wong KK. Amplification of MGC2177, PLAG1, PSMC6P, and LYN in a malignant mixed tumor of salivary gland detected by cDNA microarray with tyramide signal amplification. Cancer Genet Cytogenet 152(2):124-8, 2004. PMID: 15262430.
- Wong PK, Wong KK, Foote H. Organic Data Memory Using the DNA Approach. Communications of the ACM 46(1):95-98, 2003.
- Wong PK, Wong KK, Foote H, Thomas J. Global visualization and alignments of whole bacterial Genomes. IEEE Trans Vis Comput Graph 9(3):361-377, 2003.
- Kim JH, Herlyn D, Wong KK, Park DC, Schorge JO, Lu KH, Skates SJ, Cramer DW, Berkowitz RS, Mok SC. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 9(13):4782-4791, 2003. PMID: 14581349.
- Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 13(13):1671-1678, 2002. PMID: 11926891.
- Lipton MS, Pasa-Tolic L, Anderson GA, Anderson DJ, Auberry DL, Battista JR, Daly MJ, Fredrickson JK, Hixson KK, Kostandarithes H, Masselon C, Markillie LM, Moore RJ, Romine MF, Shen Y, Stritmatter E, Tolic N, Udseth HR, Venkateswaran A, Wong KK, Zhao R, Smith RD. Global analysis of the Deinococcus radiodurans proteome by using accurate mass tags. Proc Natl Acad Sci 99(17):11049-11054, 2002. e-Pub 2002. PMID: 12177431.
- Wong KK, Cheng RS, Mok SC. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques 30(3):670-5, 2001. PMID: 11252802.
- Mok SC, Chao J, Skates S, Wong KK, Yiu GK, Muto MG, Berkowitz RS, Cramer DW. Prostasin, a potential serum marker for ovarian cancer, identified through microarray technology. JNCI 93(19):1458-1464, 2001.
- Jensen PK, Pasa-Tolic L, Peden KK, Martinovic S, Lipton MS, Anderson GA, Tolic N, Wong KK, Smith RD. Mass spectrometric detection for capillary isoelectric focusing separations of complex protein mixtures. Electrophoresis 21(7):1372-1380, 2000. PMID: 10826683.
- Wong RMY, Wong KK, Benson NR, McClelland M. Sample sequencing of a salmonella typhimurium LT2 lambda library: Comparison to the E. coli K12 genome. FEMS Microbiology Lett 173(2):411-423, 1999.
- Markillie LM, Varnum SM, Hradecky P, Wong KK. Targeted mutagenesis by duplication insertion in the radioresistant bacterium Deinococcus radiodurans: radiation sensitivities of catalase (katA) and superoxide dismutase (sodA) mutants. J Bacteriol 181(2):666-9, 1999. PMID: 9882685.
- Romine MF, Stillwell LC, Wong KK, Thurston SJ, Sisk EC, Sensen C, Gaasterland T, Fredrickson JK, Saffer JD. Complete sequence of a 184-kilobase catabolic plasmid from sphingomonas aromaticivorans F199. J Bacteriol 181(5):1585-602, 1999. PMID: 10049392.
- Mok SC, Chan WY, Wong KK, Cheung KK, Lau CC, Ng SW, Baldini A, Colitti CV, Rock CO, Berkowitz RS. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 16(18):2381-7, 1998. PMID: 9620555.
- Wong KK, McClelland M, Stillwell LC, Sisk EC, Thurston SJ, Saffer JD. Identification and sequence analysis of a 27-kilobase chromosomal fragment containing a Salmonella pathogenicity island located at 92 minutes on the chromosome map of Salmonella enterica serovar typhimurium LT2. Infect Immun 66(7):3365-71, 1998. PMID: 9632606.
- Wong KK, Markillie LM, Saffer JD. A novel method for producing partial restriction digestion of DNA fragments by PCR with 5-methyl-CTP. Nucleic Acids Res 25(20):4169-71, 1997. PMID: 9321677.
- Mok SC, Chan WY, Wong KK, Muto MG, Berkowitz RS. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene 12(9):1895-1901, 1996. PMID: 8649850.
- Wong KK, Stillwell LC, Dockery CA, Saffer JD. Use of tagged random hexamer amplification (TRHA) to clone and sequence minute quantities of DNA--application to a 180 kb plasmid isolated from sphingomonas F199. Nucleic Acids Res 24(19):3778-83, 1996. PMID: 8871558.
- Wong KK, McClelland M. Stress-inducible genes of Salmonella typhimurium identified by arbitrarily primed PCR of RNA. Proc Natl Acad Sci 91(2):639-643, 1994.
- Mok SC, Wong KK, Chan RK, Lau CC, Tsao SW, Knapp RC, Berkowitz RS. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol Oncol 52(2):247-252, 1994. PMID: 8314147.
- Wong KK, Wong RM, Rudd KE, McClelland M. High-resolution restriction map for a 240-kilobase region spanning 91 to 96 minutes on the Salmonella typhimurium LT2 chromosome. J Bacteriol 176(18):5729-34, 1994. PMID: 8083165.
- Wong K, Mok C, Welsh J, McClelland M, Tsao S, Berkowitz R. Identification of differentially expressed RNA in human ovarian carcinoma cells by arbitrarily primed PCR fingerprinting of total RNAs. Int J Oncol 3(1):13-17, 1993. PMID: 21573318.
- Wong KK, McClelland M. A BlnI restriction map of Salmonella tyhimurium LT2 genome.A BlnI restriction map of Salmonella tyhimurium LT2 genome. J Bacteriol 174(5):1656-1661, 1992.
- Wong KK, McClelland M. Dissection of Salmonella typhimurium by use of a Tn5 derivative carrying rare restriction sites. J Bacteriol 174(11):3807-3811, 1992.
- Wong KK, Kwan HS. Transcription of glpT of Escherichia coli K12 is regulated by anaerobiosis and fnr. FEMS Microbiol Lett 94(1-2):15-18, 1992.
- Wong KK, McClelland M. PCR with 5-methyl-dCTP replacing dCTP. Nucleic Acids Res 19(5):1081-1085, 1991.
- Wong KK, Suen KL, Kwan HS. Transcription of pfl is regulated by anaerobiosis, catabolite repression, pyruvate, and oxrA: pfl::Mu dA operon fusions of salmonella typhimurium. J Bacteriol 171(9):4900-5, 1989. PMID: 2549003.
- Kwan HS, Chui HW, Wong KK. ack: Mu d1-8 (Apr lac) operon fusions of Salmonella typhimurium LT2. Mol Gen Genet 211(1):183-5, 1988. PMID: 2830464.
- Kwan HS, Wong KK. A general method for isolation of Mu d1-8 (Aprlac) operon fusions in salmonella typhimurium LT2 from Tn10 insertion strains: chlC: Mu d1-8. Mol Gen Genet 205(2):221-4, 1986. PMID: 3027501.
Invited Articles
- Malpica A, Wong KK. The molecular pathology of ovarian serous borderline tumors. Annals of Oncology 27:i16-i19, 2016.
- Wong KK, Tsai CC, Gershenson DM. BRAF mutational analysis in ovarian tumors: recent perspectives. Pathology and Laboratory Medicine International 2015(7):75-82, 2015.
- Romero I, Sun CC, Wong KK, Bast RC, Gershenson DM. Low-Grade Serous Carcinoma: New Concepts and Emerging Therapies. Gynecol Oncol 130(3):660-666, 2013. e-Pub 2013. PMID: 23707670.
- King ER, Wong KK. Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy. Recent Pat Anticancer Drug Discov 7(1):14-30, 2012. e-Pub 2011. PMID: 21875414.
- Wong KK. Oral-specific chemical carcinogenesis in mice: an exciting model for cancer prevention and therapy. Cancer Prev Res (Phila) 2(1):10-3, 2009. PMID: 19139012.
- Wong KK. Recent Developments in Anti-Cancer Agents Targeting the Ras/Raf/ MEK/ERK Pathway. Recent Pat Anticancer Drug Discov 4(1):28-35, 2009. PMID: 19149686.
- Tung CS, Wong KK, Mok SC. Biomarker discovery in ovarian cancer. Womens Health (Lond Engl) 4:27-40, 2008. PMID: 19072449.
- Mok SC, Elias KM, Wong KK, Ho K, Bonome T, Birrer MJ. Biomarker discovery in epithelial ovarian cancer by genomic approaches. Adv Cancer Res 96:1-22, 2007. PMID: 17161674.
- Mok SC, Kwong J, Welch WR, Samimi G, Ozbun L, Bonome T, Birrer MJ, Berkowitz RS, Wong KK. Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers 23(5-6):367-376, 2007. PMID: 18057520.
- Wong KK, Gershenson D. The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary. Dis Markers 23(5-6):377-387, 2007. PMID: 18057521.
- Wong KK. Rapid partial digestion of DNA fragments by PCR with 5-methyl-dCTP. Promega Notes 73:12-13, 1999.
Abstracts
- Wong KK, Kun E, Tsang YTM, Bao W, Lin S, Ren YA, RIchards JS, Gershenson DM. New mouse models with KRASG12D or KRASFV mutation in Amhr2-Cre mice develop different gynecologic tumors. Proceedings of the American Association for Cancer Research, 2018.
- Jia N, Wang J, Li Q, Tao X, Hua K, Yu Y, Baak JP, Wong KK, Feng W. Paired box 2 (PAX2) is involved in carcinogenesis and regulated by DNA methylation in endometrial cancer. Cancer Research 75(15 supplement):4768, 2015.
- Yeung TL, Leung CS, Wong KK, Mok SC. Reprogramming the TGF-beta signaling in cancer-associated fibroblasts inhibits ovarian cancer progression. Cancer Research 75(15 supplement):5066-5066, 2015.
- Leung CS, Yeung TL, Yip KP, Wong KK, Sood AK, Birrer MJ, Mok SC. CAF-derived MFAP5 promotes tumor angiogenesis and confers paclitaxel resistance in high-grade serous ovarian cancer. Cancer Research 75(15 Supplement):4184-4184, 2015.
- Kwan SY, Izaguirre DI, Cheng X, Kwan SY, Tsang YTM, Kwan HS, Wong KK. Cancer Research 75(15 Supplement):4697, 2015.
- Kwan SY, Mok SC, Wong KK, Schmandt RE, Lu KH. Ubiquitin C-terminal hydrolase L1 (UCHL1) modulates uterine papillary serous cancer progression through interaction with cyclin B1. Cancer Research 75(15 Supplement):3559-3559, 2015.
- Ren YA, Mullany LK, Wong KK, Lozano G, Herron A, Richards JS. Mutant tumor protein p53 promotes hormone responsiveness and drug resistance in ovarian cancer:Abst 169, 2014.
- Mullany LK, Ren Y, Marcinao DC, Wong KK, Crane ER, Katsonis P, Liu Z, Lichtarge O, Richards JS. Mutant p53 is a key determinant of ovarian cancer. Neoplasia of Endocrine Tissues:MON-0316, 2014.
- Tsang TYM, Izaguirre D, Gershenson D, Wong KK. Ovarian low grade serous cancer: Mutation analysis with a comprehensive 409 cancer gene panel. Proceedinf the105th Annual Meeting of the American Association for Cancer Research, San Diego, CA. Philadelphia, PA: AACR 2014(Abstract nr 1029), 2014.
- Leung SL, Yeung TL, Yip KP, Wong K, Sood AK, Birrer MJU, Mok SC. CAF-derived MFAP5 promotes ovarian tumor angiogenesis through calcium dependent LPP signaling pathway. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia, PA: AACR/ 2014(Abstract nr 1029), 2014.
- Yeung TL, Leung SL, Wong KK, Mok SC. Identification and characterization of stromal factors with clinical significance in the ovarian tumor microenvironment. Proceedings of the 105thh Annual Meeting of the American Association for Cancer Research; 2014; San Diego, CA. Philadelphia, PA(Abstract nr 4799), 2014.
- Tsuruga T, Au Yeung CL, Leung CS, Yeung TL, Wong KK, Schmandt R, Co NN, Lu KH, Mok SC. Identification of microRNAs related to chemosensitivity in ovarian cancer using Next Generation Sequencing. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1939, 2013.
- Izaguirre DI, Kwan SY, Zu Z, Tsang-Lee YT, Wong KK. GDF15 as a serum marker of cisplatin response in ovarian cancer cells. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3474, 2013.
- Kwan SY, Wong KK, Schmandt RE, Lu KH. UCHL1 as a potential therapeutic target in uterine papillary serous carcinoma. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4401, 2013.
- Yeung, TL, Leung C, Ghosh, S, Liu J, Wong, KK, Birrer, MJ, Mok, SC. TGF-beta induced stromal versican promotes cancer invasion inn advanced stage serous ovarian cancer. 2012 Proceedings, American Association for Cancer Research 52(1507), 2012.
- Leung, SL, Yeung TL, Balasubramanian L, Yip, KP, Liu, J, Wong, KK, Sood, AK, Birrer, MJ, Mok, SC. Novel stromal angiogenic factor MFAP5 in ovarian cancer progression. 2012 Proceedings, American Association for Cancer Research 52(4270), 2012.
- King, ER, Mullany, LK, Gershenson, DM, Richards, JS, Wong, KK. Nutlin-3 inducescell cycle arrest in p53 wild-type ovarian carcinomas via upregulation of p21. 2012 Proceedings, American Association for Cancer Research 52(2784), 2012.
- Matsuo K, Nishimura M, Stone RL, Komurov K, Shahzad MMK, Bottsford-Miller JN, Enomoto T, Kimura T, Ram PT, Schmeler KM, Frumovits M, Gallick GG, Wong KK, Sood AK. Targeting Src in mucinous ovarian carcinoma. 2011 Proceedings, American Association for Cancer Research 51(5032), 2011.
- King ER, Zu Z, Tsang-Lee YTM, Gershenson DM, Mok, SC, Wong, KK. Insulin-like growth factor-1 is upregulated in low-grade serous ovarian carcinoma. 2011 Proceedings American Association for Cancer Research 51(5031), 2011.
- Yeung ZP, Thompson MS, Yeung TL, Zaid TM, Wong KK, Mok, SC. Uregulation of stromal matrilin-3 expression in advanced stage high-grade serous ovarian cancer. 2011 Proceedings, American Association for Cancer Research 51(1506), 2011.
- Tsai CC, Zaid TM, Co, CN, Yeung TL, Thompson MS, Carroll A, Yeung ZP, Wong KK, Mok, SC. Expression of interferon-stimulated gene 15 is a novel prognostic predictor for patients with advanced stage high-grade serous ovarian adenocarcinoma. 2011 Proceedings, American Association for Cancer Research 51(408), 2011.
- Yeung TL, Ghosh S, Wong KK, Birrer, MJ, Mok SC. Up-regulation of stromal versican in advanced stage serous ovarian cancer modifies tumor microenvironment and promotes cancer invasion. 2011 Proceedings, American Association for Cancer Research 51(420), 2011.
- Kwan SY, Fung A, Izaguirre D, Zu Zhifei, Tsang-Lee Y, Mok S, Wong KK. Sensitivity of ovarian clear cell carcinoma cells to P13K inhibitors. 2011 Proceedings, American Association for Cancer Research 51(5037), 2011.
- Izaguirre D, Zu Z, Tsang-Lee, YT, Mok, S, Wong KK. Induction of GDF15 by cisplatin triggers apoptotic cell death in ovarian cancer cells. 2011 Proceedings, American Association for Cancer Research 51(1708), 2011.
- King ER, Zu Z, Tsang-Lee YTM, Gershenson DM, Mok, SC, Wong, KK. Regulation of the tumor suppressor gene PAEP in the transition from serous borderline ovarian tumors to low-grade serous ovarian carcinomas. J Clin Oncol 29(5074), 2011.
- Wong, KK, Mok, SC, Gershenson, DM. Characterization of low-grade ovarian serous carcinomas using TCGA data. The Cancer Genome Atlas, Scientific Symposium 117, 2011.
- Terashima K, Jsu J, Chow TW, Yu A, Nishikawa R, Matsutani M, Nakamura H, Ng HK, Su J, Bhattacharjee MB, Adekunle A, Wong KK, Leung HE, Man T, Lau CC. Genomic profiling of intracranial germ cell tumors. Neruo-Oncology 12(6):II 104, 2010.
- Yeung T, Ghosh S, Wong KK, Gutierrez-Hartman A, Kwong J, Welch W, Gershenson D, Birrer M, Mok SC. Differential nuclear Elf-3 expression in high-grade serous ovarian cancer is associated with patient survival. Gynecologic Oncology 116(S17), 2010.
- Wong K, Tsang Y, Zu Z, Mok S, Deavers MT, Birrer MJ, Wolf J, Lu KH, Gershenson DM. Insulin growth factor 1 pathway is a potential therapeutic target for low-grade ovarian serous carcinomas. Gynecologic Oncology 116(S113), 2010.
- Zaid T, Thompson, M, Wong KK, Yeung T, Yates M, Mirrer M, Mok SC. Identification of FGFR4 in the chromosome 5q31-35 prognostic amplicon as the mediator for FGF-1 signaling in high-grade serous ovarian cancer. Gynecologic Oncology 116(S125), 2010.
- Thompson M, Albitar L, Ghosh S, Wong KK, Welsch W, Birrer MJ, Mok SC. Identification of secretory stromal gene signature of the ovarian tumor microenvironment and implications for ovarian cancer progression. Gynecologic Oncology 116(S129), 2010.
- Mok S, Birrer M, Donninger H, Hao K, Ozbun L, Samini G, Vathepadiekal V, Berkowitz R, Bonome T, Wong KK. A gene signature predictive for outcome in advanced ovarian cancer identifies a novel survival factor:Microfibril-assocated glycoprotein 2. Gynecologic Oncology 116(S164), 2010.
- Song H, Tung CS, Tsang Y, Mok SC, Gershenson DM, Wong KK. PAX2 is an oncogene in type 1 ovarian cancer. 2010 Proceedings, American Association for Cancer Reserach 51, 2010.
- Thompson MS, L Albitar, Ghosh S, Wong KK, Welch WR, Birrer MJ, Mok SC. Identification of secretory stromal gene signature of the ovarian tumor microenvironment and implications for ovarian cancer progression. 2010 Proceedings, American Association for Cancer Research 51, 2010.
- Wong KK, TsangYTM, Deavers MJ, Mok SC, Gersenson DM. Clininical implications of infrequent BRAF mutation in advanced stage low-grade ovarian serous carcinomas. 2010 Proceedings, American Association for Cancer Research 51, 2010.
- Zaid T, Thompson MS, Wong KK, Yeung TS, Yeung Z, Yates MS, Birrer MJ, Mok SC. Proliferative effects of FGF1 on ovarian cancer cells correlate with FGFR4 over expression and are mediated by MAPK/ERK signaling. 2010 Proceedings, American Associaton for Cancer Research 51, 2010.
- Yeung TL, Wong KK, Gutierrez-Hartmann A, Kwong J, Welch WR, Gershenson DM, Birrer MJ, Mok SC. Elf3 as negative regulation for epithelial-mesenchymal transition in ovarian cancer. 2010 Proceedings, American Association for Cancer Research 51, 2010.
- Mok. SC, GHos S, Kwong J, Welch WR, Gershenson D, Birrer MF, Wong KK. Differential nuclear Elf-3 expression in high-grade serous ovarian cancer is associated with patient survival. 2009 Proceedings, American Association for Cancer Research 50(655), 2009.
- Chan PK, Wong KK. Anti-tumor activities of a saponin(Y3) on ovarian cancer cells. Proc Amer Assoc Cancer Res 50(167), 2009.
- Tung CS, Yeung CS, Mok SC, Birrer MJ, Lu KH, Gershenson DM, Wong KK. The Role of PAX2 as a Potential Biomarker of Low-Grade Serous Ovarian Carcinoma. SGO 2008 Winter Meeting 1339, 2008.
- Wong KK, Tung CS, Yeung C, Zu Z, Tsang YTM, Deavers M, Wolf J, Birrer MJ, Lu KH, Mok SC, Gershenson DM. Decreased expression of BCMP11 during progression from LMP to low-grade ovarian serous carcinoma. The 39th Annual Meeting of the Society of Gynecologic Oncologists 115, 2008.
- Tung CS, Yeung CS, Mok SC, Birrer MJ, Lu KH, Gershenson DM, Wong KK. The Role of PAX2 as a Potential Biomarker of Low-Grade Serous Ovarian Carcinoma. The 39th Annual Meeting of the Society of Gynecologic Oncologists 129, 2008.
- Albetar L, Wong KK, Shosh S, Bonome T, Birrer MJ, Mok SC. Identification of a stem-cell related gene signature in the stroma of high-grade advanced stage serous ovarian cancer. Proc Amer Assoc Cancer Res 49:3434, 2008.
- Wong KK, Yeung SNC, Tsang YTM, Lu KH, Birrer M, Mok SC, Gershenson DM. Genomic analysis of ovarian serous carcinoma. The 7th Joint Conference of the American Association for Cancer Research and the Japanese Cancer Association: In the Forefront of Basic and Translational Cancer Research:A13, 2007.
- Wong KK, Tsang YTM, Gu Y, Lu KH, Deavers M, Malpica A, Gershenson DM. High-resolution global genomic analysis of low-grade serous ovarian tumors reveals novel regions of allelic imbalances. The 38th Annual Meeting of the Society of Gynecologic Oncologists 94, 2007.
- Tsang YTM, Zhou Z, Lau CC, Wong KK. Over-expression of Semaphorin 3E and 5A in juvenile pilocytic astrocytomas. The 12th Scientific Meeting of the Society for Neuro-Oncology PB-17, 2007.
- Johnson ME, Park Park DC, Lee JY, Berkowitz R, Mok SC, Hao K, Wong KK, Birrer MJ. Identification of prognostic markers for high-grade advanced-stage serous ovarian cancer by oligonucleotide array comparative genomic hybridization. The 37th Annual Meeting of the Society of Gynecologic Oncologists 65, 2006.
- Fleming E, Mok SC, Tsang Y, Gershenson D, Wong KK. The use of gene identification by nonsense-mediated inhibition (GINI) to detect novel mutations in ovarian malignancies. The 37th Annual Meeting of the SGO:409, 2006.
- Shu Q, Wong KK, Adesina A, Antalffy B, Su JM, Perlaky L, Blaney S, Lau CC, Li XN. A clinical relevant orthotopic xenograft mouse model from an anaplastic medulloblastoma surgical specimen. Proceedings of AACR 47:2738, 2006.
- Man TK, Shen J, Gu J, Visvanathan J, Perlaky L, Hicks J, Johnson M, Davino N, Murray J, Helman L, Meyer W, Wai D, Triche T, Wong KK, Chintagumpala M, Lau CC. Expression profiles of osteosarcoma that can predict metastatic potential. Proceedings of AACR 47:3380, 2006.
- Johnson ME, Hao K, Wong KK, Park DC, Lee JY, Berkowitz RS, Birrer MJ, Mok SC. Identification of prognostic markers in high-grade advanced stage serous ovarian cancer by oligonucleotide array comparative genomic hybridization. Proceedings of AACR 47:3380, 2006.
- Lau CC, Man C, Gu J, Visvanathan J, Shen J, Perlaky L, Hicks J, Johnson M, Davino N, Murray J, Helman L, Meyer W, Triche T, Gorlick R, Wong KK, Chintagumpala. Expression profiles of osteosarcoma that can predict metastatic potential. Oncogenomics 2005: Dissecting Cancer Through Genome Research C40, 2005.
- Wong KK, Tsang Y, Change YM, Lau CC. Expression analysis of juvenile polocytic astrocytomas by oligonucleotide microarray reveals two potential subgroups. Oncogenomics 2005: Dissecting Cancer Through Genome Research C18, 2005.
- Wong KK, Tsang YTM, Chang YM, Lau CC. Genome-wide allelic imbalance analysis of pediatric gliomas by high-density single nucleotide polymorphic allele (SNP) array. WFNO II/EANO VI 240, 2005.
- Wong KK, Chang YM, Tsang YTM, Perlaky L, Su J, Bhattacharjee M, Adesina A, Lau CC. Expression profiling reveals two subgroups of juvenile pilocytic astrocytoma. Proceedings of AACR 95 A2847, 2004.
- Wong KK, Chang YM, Tsang YTM. cDNA microarray CGH analysis of juvenile pilocytic astrocytoma. Journal Neuro-oncology 5:G-25, 2003.
- Tsuda H, Birrer MJ, Ito YM, Ohashi Y, Wong KK, Lau CC, Gardner G, Berkowitz RS, Mok SC. Identification of DNA copy number abnormalities in microdissected tumor tissues by cDNA array comparative genomic hybridization. AACR 94th Annual Meeting Proceedings 44 1222a:241, 2003.
- Man TK, Visvanathn J, Wong KK, Perlaky L, Chintagumpala M, Hicks J, Lau C. Molecular profiles of osteosarcoma that can predict response to chemotherapy. AACR 94th Annual Meeting Proceedings 44:LB-156a, 2003.
- Wong KK, Chang YM, Tsang YTM, Rooms L, Perlaky L, Rao P, Lau CC. Genome and expression analysis of pediatric glioblastomas using cDNA microarray. Proceedings of AACR 94 R3219a:640, 2003.
- Man TK, Wong KK, Deyo J, Ma M, Culpepper P, Halter J, Lau CC. Microarray and genomic database system for pediatric tumors. NCI Director's Challenge PI Meeting, 2002.
- Hinman R, Thrall BD, Wong KK. DNA microarray technologies: a novel approach to genome research. AAAS annual Meeting and Science Innovation Exposition A104, 2002.
- Thrall BD, Cheng RS, Chin BY, Wong KK. Microarray analysis of global gene regulation by tumor necrosis factor alpha. Mol Biol Cell 12 (Suppl S):2301, 2002.
- Kwan K, Wong KK. The process of DNA sequencing. U.S. Department of Energy Journal of Undergraduate Research 2:86, 2002.
- Hinman R, Thrall BD, Wong KK. DNA microarray technologies: a novel approach to genome research. U.S. Department of Energy Journal of Undergraduate Research 2:18-24, 2002.
- Wong KK, Cheng RS. Tyramide signal amplification of dendrimer probes on cDNA microarray. NCI Director's Challenge PI Meeting 10, 2001.
- Wong KK, Cheng RS, Mok SC. Identification of differentially expressed genes in ovarian cancer cells. Toxicological Sciences 60 169a:35, 2001.
- Springer DL, Zangar RC, Wahl KL, Wong KK, Rodland KD. Proteomic analysis of changes in protein tyrosine phosphoraylation in transformed cells after treatment with a novel chemotherapeutic, carboxyamindotriazole. Toxicological Sciences 60 663a:139, 2001.
- Gibson HE, Wong KK, Yiu G, Muto M, Berkowitz R, Cramer D, Mok SC. Clinical application of microarray technology: creatine kinase B is an upregulated gene in epithelial ovarian cancer and shows promise as a serum marker. AACR 92nd Annual Meeting Proceedings 42 3286a:610, 2001.
- Yiu GK, Chao J, Wong KK, Cramer DW, Berkowitz RS, Mok SC. Prostasin, a potential serum marker for the early detection of ovarian cancer. AACR 92nd Annual Meeting Proceedings 42 3994a:744, 2001.
Book Chapters
- Crane ER, Wong KK. The Therapeutic Promise of Anti-Cancer Drugs Against the Ras/Raf/MEK/ERK Pathway. In: Topics in Anti-Cancer Research. Bentham Science: USA, 63-94, 2013.
- Erin R. King and Kwong-Kwok Wong. Steroid hormones and ovarian cancer. In: Steriods - Clinical Aspect. In-Tech, 2011.
- Tung CS, Wong KK,. Molecular signatures in ovarian cancer. In: Field Cancerization: Basic Science and Clinical Applications. Nova Science Publishers, Inc: New York, Chapter 21, 2010.
- Mok SC, Wong KK, Lu KH, Munger K, Nagymanyoki Z. Molecular Basis of Gynecologic Diseases, Chapter 23. In: Molecular Pathology: The molecular basis of human disease. Academic Press-Elsevier, 465-488, 2009.
- Wong KK. Use of single nucleotide polymorphism array for tumor aberrations in gene copy numbers. In: Pharmacogenomics, Anticancer Drug Discovery and Response. Humana Press: Totowa, NJ, 2007.
- Wong KK, Kanno J, Cheng RS, Sasser L, Morris J, Anderson L, Pounds J, Inoue T. Application of cDNA microarray for uterotrophic assay. In: Toxicogenomics. Springer-Verlag: Tokyo, Japan, 2003.
- Wong KK, Chen RS, Kim JH, Mok SC. Gene expression analysis of ovarian tumors with a cDNA microarray containing ovarian tumor specific clones. In: Perspective in Gene Expression. Eaton Publishing: Natick, MA, 2003.
- Wong KK, Cheng RS, Berkowitz RS, Mok SC. Gene expression analysis of ovarian cancer cells by CDNA microarray. In: Microarray and Cancer. Eaton Publishing: Natick, MA, 2002.
- Mok SC, Wong KK, Chan WY, Lau CC, Sager R, Berkowitz RS. Changes in gene expression. In: Ovarian Cancer. Isis Medical Media Ltd: Oxford, UK, 25-33, 1998.
- McClelland M, Wong KK, Sanderson KE. Physical Mapping and Fingerprinting of Bacterial Genomes using rare cutting restriction enzymes. In: Bacterial Genomes: Physical Structure and Analysis. Chapman and Hall, 1998.
- Wong KK, Cheng R, Saffer JD, Ralph D, Welsh J, McClelland M. DNA fingerprinting by arbitrarily primed PCR (RAPDs). In: Molecular Microbial Ecology Manual. Kluwer Academic Publishers: THe Netherlands, 63-76, 1996.
- Liu SL, Wong KK, McClelland M, Sanderson KE. Construction of a physical map of the genome of Salmonella typhimurium. In: The Biology of Salmonella. Plenum Press: New York, 41-50, 1993.
- Wong KK, Kwan HS. A novel mutation causing deficiency in lactate production of Salmonella typhimurium during mixed acid fermentation. In: Recent Advances in Applied Biology and Biotechnology. CUHK Press, 293-300, 1988.
Grant & Contract Support
| Title: | Steroid hormones regulate ovarian cancer progression and metastasis |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | A Novel Mouse Model for Uterine Leiomyoma |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Rational Development of Immune Therapy for Low-Grade Ovarian Serous Carcinoma to Overcome MEK Inhibitor Resistance |
| Funding Source: | Department of Defense (DOD) |
| Role: | Principal Investigator |
| Title: | A novel uterine leiomyosarcoma mouse model for therapeutic development |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified March 14, 2024